Get the Stockscreener App
31.40
1.04%
-0.33
After Hours:
31.57
0.17
+0.54%
Viking Therapeutics Inc stock is traded at $31.40, with a volume of 1.58M.
It is down -1.04% in the last 24 hours and down -15.55% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$31.73
Open:
$31.75
24h Volume:
1.58M
Relative Volume:
0.46
Market Cap:
$3.55B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-33.76
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-6.32%
1M Performance:
-15.55%
6M Performance:
-8.77%
1Y Performance:
-6.16%
1-Day Range:
$31.20
$32.14
1-Week Range:
$31.20
$34.98
52-Week Range:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.40 | 3.59B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-25 | Initiated | Canaccord Genuity | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
2 Biotech Stocks Set to Rebound in 2026 - The Globe and Mail
Viking Therapeutics’ Obesity Drug Candidate Gains Momentum with Phase 2 Publication - AD HOC NEWS
Assessing Viking Therapeutics (VKTX) After Recent Pullback And Ongoing Pipeline Headlines - simplywall.st
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? - Yahoo Finance
Viking Therapeutics Stock Analysis: Growth Narrative Remains Compelling - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline - Insider Monkey
The Technical Signals Behind (VKTX) That Institutions Follow - Stock Traders Daily
3 Growth Stocks to Invest $1,000 in Right Now - The Motley Fool
The Best Stocks to Invest $40 in to Start the New Year Off Right - Finviz
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts - sharewise.com
Viking Therapeutics Shares Slide Amid Analyst Downgrade and Earnings Concerns - AD HOC NEWS
Viking Therapeutics (VKTX) Is Down 5.0% After Phase 2 VK2735 Data And Phase 3 Updates – Has The Bull Case Changed? - simplywall.st
Viking Therapeutics, Inc. (VKTX) stock dips while market gains: Key facts - MSN
Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly - FinancialContent
Assessing Viking Therapeutics (VKTX) Valuation As Shares Rebound Over The Past Week - Yahoo Finance
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 - Finviz
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Downgraded by Zacks Research to Strong Sell - MarketBeat
Assessing Viking Therapeutics (VKTX) Valuation After VK2735 Phase 2 Success And Phase 3 Trial Progress - simplywall.st
Can Viking Therapeutics Make a Turnaround This Year? - NAI500
2 Bargain Stocks You Can Buy for Less Than $100 Right Now - The Globe and Mail
Viking Therapeutics' Price Target of $93.39 Implies 175% Upside Potential - Intellectia AI
Viking Therapeutics (VKTX) Faces Challenges, Analysts Set Price Target of $93.39, Potential Upside of 175% - Intellectia AI
1 Stock That Could Soar by 175%, According to Wall Street - Finviz
Upcoming Oppenheimer Virtual Meeting Featuring VKTX - GuruFocus
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? - AOL.com
3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026 - Finviz
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 - MarketBeat
Viking Therapeutics, Inc. (VKTX) Investor Outlook: A Biotech Stock with 175% Potential Upside - directorstalkinterviews.com
Published on: 2026-01-18 12:53:17 - baoquankhu1.vn
Viking Therapeutics Stock (VKTX) Opinions on VK2735 Obesity Drug Results - Quiver Quantitative
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Volume Summary: What is AEISs valuation compared to sector2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Viking Therapeutics: A Stock at a Crossroads Amid Obesity Drug Ambitions - AD HOC NEWS
Is Viking Therapeutics (VKTX) Now Attractive After A Strong DCF Upside Signal - Yahoo Finance
Viking Therapeutics Stock Navigates a Week of High Volatility - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
The Escalator: AstraZeneca, Viking Therapeutics, VML Health and more - Medical Marketing and Media
M&A Speculation Fuels Rally in Viking Therapeutics Shares - AD HOC NEWS
Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress - simplywall.st
Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook - Finviz
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals - Stocktwits
Viking Therapeutics Unveils Promising Phase 2 Clinical Success, Fuels Stock Surge - timothysykes.com
Precision Trading with Viking Therapeutics Inc. (VKTX) Risk Zones - Stock Traders Daily
Viking Therapeutics (NASDAQ:VKTX) Trading 8.3% HigherShould You Buy? - MarketBeat
$VKTX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals - TechStock²
SG Americas Securities LLC Acquires 81,519 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Positioning in the Competitive Obesity Drug Arena - AD HOC NEWS
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):